Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Nieder, Carsten ^a,b   Haukland, Ellinor ^a   Pawinski, Adam ^a   Dalhaug, Astrid ^a  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; HEMOGLOBIN; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE METASTASIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CAUSE OF DEATH; COHORT ANALYSIS; COMMUNITY HOSPITAL; CONTROLLED STUDY; DISEASE ASSOCIATION; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK FACTOR; SUBDURAL HEMATOMA; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; BLOOD; BONE TUMOR; ERYTHROCYTE TRANSFUSION; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; NORWAY; PATHOLOGY; PROSTATE TUMOR; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BONE NEOPLASMS; ERYTHROCYTE TRANSFUSION; HEMOGLOBINS; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NORWAY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAXOIDS; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953311958     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-284     Document Type: Article

References (13)

1. Hernes E, Kyrdalen A, Kvåle R, Hem E, Klepp O, Acrona K, Fosså SD. Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry. BJU Int 2009, 105:805-11. 10.1111/j.1464-410X.2009.08834.x, 19735258.
2. Meulenbeld HJ, Hamberg P, de Wit R. Chemotherapy in patients with castration-resistant prostate cancer. Eur J Cancer 2009, 45(Suppl 1):161-171. 10.1016/S0959-8049(09)70029-2, 19775615.
3. Nalesnik JG, Mysliwiec AG, Canby-Hagino E. Anemia in men with advanced prostate cancer: incidence, etiology, and treatment. Rev Urol 2004, 6:1-4. 1472681, 16985564.
4. Khafagy R, Shackley D, Samuel J, O'Flynn K, Betts C, Clarke N. Complications arising fin the final year of life in men dying from advanced prostate cancer. J Palliat Med 2007, 10:705-711. 10.1089/jpm.2006.0185, 17592982.
5. Geenen RW, Delaere KP, van Wersch JW. Haematological variables in prostatic carcinoma patients. Acta Urol Belg 1996, 64:21-26.
6. Curtis KK, Adam TJ, Chen SC, Pruthi RK, Gornet MK. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review. Aging Male 2008, 11:157-161. 10.1080/13685530802172438, 18937151.
7. Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, DeLoughery TG, Crwaford ED, . Southwest Oncology Group The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894. Cancer 2006, 107:489-496. 10.1002/cncr.22029, 16804926, Southwest Oncology Group.
8. Beer TM, Tangen CM, Bland LB, Thompson IM, Crawford ED. Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group Study 8894. J Urol 2004 172:2213-2217. Erratum in 174: 1156.
9. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003, 21:1232-1237. 10.1200/JCO.2003.06.100, 12663709.
10. Nakashima J, Kikuchi E, Miyajima A, Nakagawa K, Oya M, Ohigashi T, Murai M. Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases. Urol Int 2008, 80:129-133. 10.1159/000112601, 18362480.
11. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009, 373:1532-1542. 10.1016/S0140-6736(09)60502-X, 19410717.
12. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE, . American Society of Clinical Oncology; American Society of Hematology Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice update. J Clin Oncol 2008, 26:132-149. 10.1200/JCO.2007.14.3396, 17954713, American Society of Clinical Oncology; American Society of Hematology.
13. Greil R, Thödtman R, Roila F, . ESMO Guidelines Working Group Erythropoietins in cancer patients: ESMO recommendations for use. Ann Oncol 2008, 19(Suppl 2):ii113-15. 10.1093/annonc/mdn106, 18456746, ESMO Guidelines Working Group.